Utama › Melanoma › New York

Kajian klinikal Melanoma di New York

50 kajian untuk Melanoma sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

START New York Long Island LLC, Lake Success

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan

Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Roswell Park Cancer Institute IDS, Buffalo
Memorial Sloan Kettering Hospital, New York

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06172478

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

NYU Langone Hospital - Long Island, Mineola
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

New York Oncology Hematology, Albany

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06246916

Pan-tumor MRD Study

Guthrie Lourdes Memorial Hospital (GLMH), Binghamton
New York Cancer & Blood Specialists, Shirley

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06605404

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

Roswell Park Cancer Institute, Buffalo
Glens Falls Hospital, Glens Falls
NYU Langone Hospital - Long Island, Mineola
dan 4 lagi

Mengambil pesertaFasa 3

Umur 75 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07068074

Intratumoral N17350 in Advanced Solid Tumors

Roswell Park Comprehensive Cancer Center, Buffalo

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07339176

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

Weill Cornell Medicine, New York

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07661966

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT04752826

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0142, Buffalo
Local Institution - 0170, New York
Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07492680

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT05607095

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

START Cancer Research New York-Long Island, Lake Success

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07287917

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06284590

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
dan 1 lagi

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT05837767

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NYU Langone, New York

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT04913285

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Memorial Sloan Kettering Hospital, New York

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07070232

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

NYU Langone Hospital - Long Island, Mineola
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT05896839

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

Mengambil pesertaFasa 1/2

12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

Project: Every Child for Younger Patients With Cancer

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
dan 12 lagi

Mengambil pesertaKajian pemerhatian

Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

NYU Langone Health, New York

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT07504796

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Weill Cornell Medicine - New York Presbyterian Hospital, New York

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT06425926

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT05859074

A Study of MGC026 in Participants With Advanced Solid Tumors

START-New York Long Island, Lake Success

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT06242470

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NYU Langone Health, New York
Icahn School of Medicine At Mount Sinai Prime, New York
Clinical Research Alliance, Inc, Westbury
dan 1 lagi

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Roswell Park Cancer Institute, Buffalo

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 28 Jul 2026 · NCT06150664

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Memorial Sloan Kettering (Melanoma/NSCLC), New York

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT06060613

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Call for Information (Investigational Site 0031), New York

Mengambil pesertaFasa 1/2

6 Months – 17 Years · Semua jantina · Dikemas kini 6 Jul 2026 · NCT02332668

Integrated Cancer Repository for Cancer Research

C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
Faxton St. Luke's Healthcare, Mohawk Valley, Utica

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan

Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Weill Medical College of Cornell University, New York
Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 1/2

Umur 18 hingga 70 · Semua jantina · Dikemas kini 11 Jun 2026 · NCT05361174

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA04-0, New York

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06953089

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Perlmutter Cancer Center at NYU Langone Health, New York
Memorial Sloan-Kettering Cancer Center, New York
Columbia University, New York

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mei 2026 · NCT03686124

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center - 1275 York Ave, New York
Northwell Health Cancer Institute, New York

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT07015190

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Northwell Health, Lake Success

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 28 Apr 2026 · NCT06413680

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Roswell Park, Buffalo
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Columbia University Medical Center, New York
dan 1 lagi

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 20 Apr 2026 · NCT06326411

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 2/3

Semua umur · Semua jantina · Dikemas kini 2 Apr 2026 · NCT06581406

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Glens Falls Hospital, Glens Falls
Queens Hospital Center, Jamaica
Montefiore Medical Center-Einstein Campus, The Bronx
dan 1 lagi

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Northwell Health Cancer Institute - Zuckerberg Cancer Center, Lake Success
Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Feb 2026 · NCT05549297

ACTengine® IMA203 Combined With mRNA-4203

Memorial Sloan Kettering Cancer Center, New York

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jan 2026 · NCT06946225

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.